Hyperphosphatemia of chronic kidney disease.

[1]  Xianwu Li,et al.  BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. , 2008, Atherosclerosis.

[2]  L. Chaudhary,et al.  The mechanism of phosphorus as a cardiovascular risk factor in CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[3]  M. Mohammadi,et al.  The parathyroid is a target organ for FGF23 in rats. , 2007, The Journal of clinical investigation.

[4]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[5]  K. White,et al.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. , 2007, Journal of musculoskeletal & neuronal interactions.

[6]  H. Murer,et al.  Phosphate transporters: a tale of two solute carrier families. , 2007, American journal of physiology. Renal physiology.

[7]  Jason R. Stubbs,et al.  Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. , 2007, Journal of the American Society of Nephrology : JASN.

[8]  Y. Bogaert,et al.  Characterization of Phosphate Transport in Rat Vascular Smooth Muscle Cells: Implications for Vascular Calcification , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[9]  M. Rué,et al.  Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  P. Raggi,et al.  Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. , 2007, Kidney international.

[11]  R. Detrano,et al.  Coronary artery calcification and myocardial perfusion in asymptomatic adults: the MESA (Multi-Ethnic Study of Atherosclerosis). , 2006, Journal of the American College of Cardiology.

[12]  Alex J. Brown,et al.  FGF-23 and sFRP-4 in Chronic Kidney Disease and Post-Renal Transplantation , 2006, Nephron Physiology.

[13]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[14]  Jason R. Stubbs,et al.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  Xianwu Li,et al.  Role of the Sodium-Dependent Phosphate Cotransporter, Pit-1, in Vascular Smooth Muscle Cell Calcification , 2006, Circulation research.

[16]  M. Razzaque,et al.  Premature aging‐like phenotype in fibroblast growth factor 23 null mice is a vitamin D‐mediated process , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  K. Rosenblatt,et al.  Regulation of Fibroblast Growth Factor-23 Signaling by Klotho* , 2006, Journal of Biological Chemistry.

[18]  K. Hruska,et al.  New insights into mineral and skeletal regulation by active forms of vitamin D. , 2006, Kidney international.

[19]  R. Foley,et al.  Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. , 2005, Journal of the American Society of Nephrology : JASN.

[20]  K. Hruska,et al.  Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. , 2005, Journal of the American Society of Nephrology : JASN.

[21]  B. Kestenbaum,et al.  Serum phosphate levels and mortality risk among people with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[22]  L. Calvi,et al.  The interplay of osteogenesis and hematopoiesis , 2004, The Journal of cell biology.

[23]  R. Virmani,et al.  Decorin Promotes Aortic Smooth Muscle Cell Calcification and Colocalizes to Calcified Regions in Human Atherosclerotic Lesions , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[24]  M. Razzaque,et al.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[25]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[26]  Michael Pignone,et al.  Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. , 2004, Archives of internal medicine.

[27]  K. Miyamoto,et al.  Physiological regulation of renal sodium-dependent phosphate cotransporters. , 2004, The Japanese journal of physiology.

[28]  D. Miao,et al.  Inactivation of the 25-Hydroxyvitamin D 1α-Hydroxylase and Vitamin D Receptor Demonstrates Independent and Interdependent Effects of Calcium and Vitamin D on Skeletal and Mineral Homeostasis* , 2004, Journal of Biological Chemistry.

[29]  S. Ott,et al.  Osteoporosis in chronic kidney disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  L. Chaudhary,et al.  Differential growth factor control of bone formation through osteoprogenitor differentiation. , 2004, Bone.

[31]  H. Murer,et al.  Regulation of Na/Pi transporter in the proximal tubule. , 2003, Annual review of physiology.

[32]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[33]  Haiyang Huang,et al.  Identification of the haematopoietic stem cell niche and control of the niche size , 2003, Nature.

[34]  D. Scadden,et al.  Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.

[35]  G. Beck.  Inorganic phosphate as a signaling molecule in osteoblast differentiation , 2003, Journal of cellular biochemistry.

[36]  G. London,et al.  Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  K. Hruska,et al.  BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. , 2003, Journal of the American Society of Nephrology : JASN.

[38]  J. Aubin,et al.  Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Arking,et al.  KLOTHO allele status and the risk of early-onset occult coronary artery disease. , 2003, American journal of human genetics.

[40]  N. Chen,et al.  Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. , 2003, Kidney international.

[41]  H. Mayan,et al.  Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. , 2002, The Journal of clinical endocrinology and metabolism.

[42]  P. Raggi,et al.  Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? , 2002, Journal of the American College of Cardiology.

[43]  I. Mian,et al.  Association of human aging with a functional variant of klotho , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Geusens,et al.  Differential Expression of Bone Matrix Regulatory Proteins in Human Atherosclerotic Plaques , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[45]  C. Stehman-Breen,et al.  Bone Mineral Density Measurements in Dialysis Patients , 2001, Seminars in dialysis.

[46]  M. Coco,et al.  Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  M. McKee,et al.  Phosphate regulation of vascular smooth muscle cell calcification. , 2000, Circulation research.

[48]  A. Dusso,et al.  A novel mechanism for skeletal resistance in uremia. , 2000, Kidney international.

[49]  E. Moran,et al.  Phosphate is a specific signal for induction of osteopontin gene expression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Craig S. Wong,et al.  Increased risk of hip fracture among patients with end-stage renal disease. , 2000, Kidney international.

[51]  W. Goodman,et al.  Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism , 2000, Pediatric Nephrology.

[52]  M. Traebert,et al.  Regulation of small intestinal Na-Pi type IIb cotransporter by dietary phosphate intake. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[53]  P. Eskildsen,et al.  Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. , 1999, Kidney international.

[54]  G. London,et al.  Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[55]  C. Stehman-Breen,et al.  Racial differences in bone mineral density and bone loss among end-stage renal disease patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[56]  T. Latifi,et al.  Diet-induced Diabetes Activates an Osteogenic Gene Regulatory Program in the Aortas of Low Density Lipoprotein Receptor-deficient Mice* , 1998, The Journal of Biological Chemistry.

[57]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[58]  Y. Fukui,et al.  Effects of dietary Pi on the renal Na+-dependent Pi transporter NaPi-2 in thyroparathyroidectomized rats. , 1998, The Biochemical journal.

[59]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[60]  F. Verrey,et al.  Identification of a new gene product (diphor-1) regulated by dietary phosphate. , 1997, American journal of physiology. Renal physiology.

[61]  M. Levi,et al.  Molecular Regulation of Renal Phosphate Transport , 1996, The Journal of Membrane Biology.

[62]  E. Slatopolsky,et al.  Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[63]  H. Takagi,et al.  Clonal Analysis of Nodular Parathyroid Hyperplasia in Renal Hyperparathyroidism , 1996, World Journal of Surgery.

[64]  Mei Wang,et al.  Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[65]  L. Demer.  A skeleton in the atherosclerosis closet. , 1995, Circulation.

[66]  J. Silver,et al.  Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. , 1995, The Journal of clinical investigation.

[67]  G. Segre,et al.  Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. , 1994, Kidney international.

[68]  P. Weissberg,et al.  High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[69]  D. Sherrard,et al.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. , 1993, Kidney international.

[70]  K. Kurokawa,et al.  Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. , 1993, The Journal of clinical investigation.

[71]  K. Watson,et al.  Bone morphogenetic protein expression in human atherosclerotic lesions. , 1993, The Journal of clinical investigation.

[72]  H. DeLuca,et al.  Metabolism and excretion of 3H-1,25-(OH)2-vitamin D3 in healthy adults. , 1978, The Journal of clinical endocrinology and metabolism.

[73]  A. Robson,et al.  Control of phosphate excretion in uremic man. , 1968, The Journal of clinical investigation.

[74]  N. Bricker,et al.  The control of phosphate excretion in uremia. , 1966, The Journal of clinical investigation.

[75]  K. Hruska,et al.  Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. , 2007, Journal of the American Society of Nephrology : JASN.

[76]  C. Stehman-Breen.  Osteoporosis and chronic kidney disease. , 2004, Seminars in nephrology.

[77]  J. Silver,et al.  The Effects of Calcium, Phosphate, and Vitamin D , 1995 .

[78]  G. Segre,et al.  Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. , 1994, Kidney international.